Anika Therapeutics | ANIK - Assets


Anika Therapeutics reported $183.47M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Abbott USD 108.25B 968M Sep/2026
Agenus USD 172.69M 13.76M Jun/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.23B 123.49M Sep/2026
Integra LifeSciences USD 3.51B 55.69M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merit Medical Systems USD 2.92B 61.29M Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 130.29B 1.23B Sep/2026
Smith & Nephew USD 11.01B 321M Jun/2026
Stryker USD 47.25B 683M Sep/2026
Veracyte USD 1.57B 86.89M Sep/2026
Xencor USD 770.5M 45.54M Sep/2026
Zimmer Biomet Holdings USD 23.54B 740.8M Sep/2026